MethyLPREDNISolone Acetate Injectable Suspension, USP, 200mg/5mL (40 mg/mL), 5 mL multi-dose vial, Rx only, MFG: Teva Pharma USA, NDC 0703-0043-01
Published June 15, 2022 · Recall initiated: April 13, 2022
Summary
FDA records drug Class II recall D-1071-2022, published June 15, 2022 and initiated April 13, 2022. Recalling firm: Mckesson Medical-Surgical Inc. Corporate Office; Status: Terminated; Reported quantity: 65 cartons/1 vial each; Lot: McKesson Medical-Surgical (MMS) is not able to identify the particular lot number received by a particular consignee for the recalled prescription products. Each letter includes the date it was distributed to customers and the dates that impacted product may have been shipped to the customer. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
cGMP deviations: Temperature abuse
What to do
Voluntary: Firm initiated · Letter
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Mckesson Medical-Surgical Inc. Corporate Office
- Distributor
- USA nationwide.
- Lot
- McKesson Medical-Surgical (MMS) is not able to identify the particular lot number received by a particular consignee for the recalled prescription products. Each letter includes the date it was distributed to customers and the dates that impacted product may have been shipped to the customer.
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDABENLYSTA (belimumab) for injection, 400 mg/20 mL vial, Rx only, NDC 49401-102-01, GSK.July 30, 2025
- FDAPROLIA (denosumab), injection, 60mg/mL, For Subcutaneous Use Only, Rx Only, Manufactured by: Amgen Inc.,July 30, 2025
- FDAEVENITY, (romosozumab -aqqg) injection, 105mg/1.17 mL, For Subcutaneous Use Only, Rx Only, Manufactured by:July 30, 2025
- FDASEKISUI DIAGNOSTICS LLC SERUM HCG OSOMGENZME CONTROL SET.June 4, 2025
- FDAMethyLPREDNISolone Acetate Injectable Suspension, USP, 40 mg/mL, packaged in a) 1 mL single dose vial (NDCJune 15, 2022
- FDAMethyLPREDNISolone Acetate Injectable Suspension USP, 400 mg/10 mL (40 mg/mL), 10 mL multi-dose vial, Rx only,June 15, 2022
Questions about this recall
Was MethyLPREDNISolone Acetate Injectable Suspension, USP, 200mg/5mL (40 mg/mL), 5 mL multi-dose vial, Rx only, MFG: Teva Pharma USA, NDC 0703-0043-01 recalled?
Yes. FDA published recall D-1071-2022 on June 15, 2022. Reported hazard: cGMP deviations: Temperature abuse
What should I do if I have this product?
Voluntary: Firm initiated · Letter